ArticleBioMed research international2014
Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting.
Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 58 citations in OpenAlex.
- Essential information about nanotechnology in cardiology.Annals of medicine and surgery (2012) · 2025Review
- A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy.Molecular cancer · 2024Review
- Review
- Synthesis & Evaluation of Novel Mannosylated Neoglycolipids for Liposomal Delivery System Applications.Pharmaceutics · 2022Article
- Review
- Nanotechnology in cardiac stem cell therapy: cell modulation, imaging and gene delivery.RSC advances · 2021Review
- Improving the Utility of a Dynorphin Peptide Analogue Using Mannosylated Glycoliposomes.International journal of molecular sciences · 2021Article
- Synthesis and Characterization of Mannosylated Formulations to Deliver a Minicircle DNA Vaccine.Pharmaceutics · 2021Article
- Retracted: Mannosylated Chitosan Nanoparticles for Delivery of Antisense Oligonucleotides for Macrophage Targeting.BioMed research international · 2021Article
- Modulation of Macrophages M1/M2 Polarization Using Carbohydrate-Functionalized Polymeric Nanoparticles.Polymers · 2020Review
- Mannose receptor targeted bioadhesive chitosan nanoparticles of clofazimine for effective therapy of tuberculosis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Article
- Nanotechnology as a Platform for the Development of Injectable Parenteral Formulations: A Comprehensive Review of the Know-Hows and State of the Art.Pharmaceutics · 2020Review
- Chitosan Nanocomplexes for the Delivery of ENaC Antisense Oligonucleotides to Airway Epithelial Cells.Biomolecules · 2020Article
- Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases.International journal of nanomedicine · 2020Review
- Nanomedicine for Gene Delivery for the Treatment of Cardiovascular Diseases.Current gene therapy · 2019Review
- The different ways to chitosan/hyaluronic acid nanoparticles: templated vs direct complexation. Influence of particle preparation on morphology, cell uptake and silencing efficiency.Beilstein journal of nanotechnology · 2019Article
- Article
- Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles.Journal of cellular and molecular medicine · 2017Review
- Micro- and nanoparticulates for DNA vaccine delivery.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Sulfated Seaweed Polysaccharides as Multifunctional Materials in Drug Delivery Applications.Marine drugs · 2016Review
Corrections and comments
- Retraction · 2021-02-19Author Unresponsive · Concerns/Issues about Data · Concerns/Issues about Image · Duplication of/in Image · Manipulation of Images · Original Data and/or Images not Provided and/or not Available ·
- Retracted
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic potential of antisense oligonucleotides (ASODN) is primarily dependent upon its safe and efficient delivery to specific cells overcoming degradation and maximizing cellular uptake in vivo. The present study focuses on designing mannosylated low molecular weight (LMW) chitosan nanoconstructs for safe ODNs delivery by macrophage targeting. Mannose groups were coupled with LMW chitosan and characterized spectroscopically. Mannosylated chitosan ODN nanoparticles (MCHODN NPs) were formulated by self-assembled method using various N/P ratio (moles of amine groups of MCH to phosphate moieties of ODNs) and characterized for gel retardation assay, physicochemical characteristics, cytotoxicity and transfection efficiency, and antisense assay. Complete complexation of MCH/ODN was achieved at charge ratio of 1:1 and above. On increasing the N/P ratio of MCH/ODN, particle size of the NPs decreased whereas zeta potential (ZV) increased. MCHODN NPs displayed much higher transfection efficiency into Raw 264.7 cells (bears mannose receptors) than Hela cells and no significant toxicity was observed at all MCH concentrations. Antisense assay revealed that reduction in lipopolysaccharide (LPS) induced serum TNF-α is due to antisense activity of TJU-2755 ODN (sequence complementary to 3'-UTR of TNF-α). These results suggest that MCHODN NPs are acceptable choice to improve transfection efficiency in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.